Overview
AI-powered drug discovery platform combining biology, chemistry, and ML at scale.
Details
Recursion (Nasdaq: RXRX) operates one of the largest biological datasets in pharma, generating petabytes of phenomic, transcriptomic, and chemical data to train ML models. Its Recursion OS supports an internal pipeline plus partnerships with Roche, Bayer, and Sanofi. Recursion merged with Exscientia in 2024.
Tags
drug-discovery, ai-pharma, phenomics, foundation-models, public-company, partnerships